沃瑞沙(赛沃替尼) 获得中国国家药监局常规批准用于治疗局部晚期或转移性MET外显子14非小细胞肺癌

每日经济新闻
14 Jan

每经AI快讯,据和黄医药官微消息,和黄医药今日宣布沃瑞沙®(赛沃替尼) 用于治疗具有间质-上皮转化因子 ("MET") 外显子14跳变的局部晚期或转移性非小细胞肺癌成人患者的新适应症上市申请已取得中国国家药品监督管理局批准。国家药监局亦将早前沃瑞沙®在经治患者中的附条件批准转为常规批准。沃瑞沙®在中国的新适应症将扩展至同时涵盖初治和经治患者。(文章来源:每日经济新闻)

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10